Optispan Collaborates in Groundbreaking RAPID Clinical Trial to Tackle Periodontal Disease and Aging

For Immediate Release

Seattle, WA – 12/4/23 – Optispan, a leading healthcare technology company based in Seattle, is proud to announce its collaboration in the landmark RAPID clinical trial, which has received approval from the U.S. Food and Drug Administration (FDA). This pioneering study, led by Dr. Jonathan An at the University of Washington, aims to evaluate the effectiveness of rapamycin in older adults with periodontal disease, a chronic oral inflammatory disease linked to other age-related conditions such as heart disease, diabetes, and Alzheimer’s Disease.

The RAPID trial stands out as the first and only study of its kind, targeting the mTOR pathway via rapamycin to attenuate, and potentially reverse, periodontal disease. This approach signifies a shift from merely addressing the symptoms of periodontal disease to tackling the underlying biological aging process.

Optispan CEO, Dr. Matt Kaeberlein, expresses his enthusiasm for this collaboration: "We are thrilled to be part of the RAPID trial, a significant step in our mission towards Optimal Healthspans for Everyone. This trial embodies our commitment to proactive, science-based healthcare and marks a pivotal moment in the treatment of age-related diseases."

Optispan’s Chief Medical Officer, Dr. George Haddad, adds, “Our participation in the RAPID trial aligns perfectly with our philosophy of Healthspan Medicine and our systems view of health. By monitoring biological aging biomarkers in participants, we aim to gather invaluable data that could redefine the understanding and management of periodontal disease and its systemic implications.”

Enrolled participants in the RAPID trial will receive comprehensive exams, rapamycin treatment, and 3-4 dental cleanings, including deep cleanings, free of charge, in addition to compensation for their time. Optispan’s role in monitoring biological aging biomarkers is expected to provide critical insights into the broader health impacts of the treatment.

For more information on the RAPID trial, to sign up as a participant, or to support through donations, please visit www.rapamycintrial.com.

Optispan is excited to contribute to this groundbreaking research and hopeful that the results from the RAPID trial will advance next-generation treatment strategies for periodontal disease and enhance our understanding of the intricate relationship between oral health and aging.

About Optispan

Optispan is a healthcare technology company based in Seattle, Washington, committed to advancing Healthspan Medicine.

Contact:

Tara Mei
Head of Strategy
Optispan
tara@optispan.life